


# New Resource

## COVID-19 Outpatient Therapeutics Decision Guide



*Limited use of bamlanivimab/etesevimab and REGEN-COV as they are not expected to be active against the Omicron variant<sup>1</sup>*

<sup>1</sup> Refer to the NIH COVID-19 Treatment Guidelines Panel's Statement on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies or Remdesivir for the Treatment of Covid-19 in Nonhospitalized Patients when Omicron is the Predominant Circulating Variant, literature (Dec 22, 2021) Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients; DOI: 10.1056/NEJMoa2115846)  
<sup>2</sup> COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease in either the outpatient or inpatient setting (COVID-19 Convalescent Plasma EUA)